Skip to content

Comparison of the effects of esketamine, sufentanil, or lidocaine combined with propofol on tussis reflection during upper gastroscopy: a randomised, two centre, three-blind, controlled trial

Comparison of the effects of esketamine, sufentanil, or lidocaine combined with propofol on tussis reflection during upper gastroscopy: a randomised, two centre, three-blind, controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062426
Enrollment
Unknown
Registered
2022-08-05
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

P group:Single administration of propofol
P + S group:Administration of propofol and sufentanil in combination
P + K group:Administration of propofol and esketamine in combination
P + L group:Administration of propofol and lidocaine in combination

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Undergo diagnostic upper GI endoscopy under deep propofol sedation; 2. Meet the classification I–III of the American Society of Anesthesiologists (ASA); 3. >18 years old; 4. Give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Allergic reaction to planned medication; 2. Gravis myasthenia; 3. History of psychological problems or psychiatric disease; 4. Morbid obesity/obstructive sleep apnea; 5. Acute upper respiratory infections; 6. Asthma at acute stage; 7. History of unregulated or malignant hypertension, significant ischemic heart disease, severe arrhythmia; 8. Uncontrolled hyperthyroidism; 9. Severe cardiac, liver, and kidney dysfunction and coagulation disorders; 10. Acute upper GI haemorrhage with shock; 11. Severe anaemia; 12. GI obstruction with gastric retention; 13. Seizure disorders, long-term history of sedative and analgesic drug use, and history of allergy; 14. Increased intracranial pressure.

Design outcomes

Primary

MeasureTime frame
Frequency of tussis, nausea and vomiting, and/or body movements;Pharmacoeconomic outcomes;Mini-mental State Examination, MMSE;Metabolic equivalent, MET;Sleep changes;

Secondary

MeasureTime frame
Time of the addition of the first drug;Time of recovery from anaesthesia;Perioperative propofol doses;Incidence of perioperative adverse events;Incidence of postoperative adverse events;

Countries

China

Contacts

Public ContactHou Haijun

Beijing Friendship Hospital, Capital Medical University

77790690@qq.com+86 18612568228

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026